We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




“Live” Cyberplasm Microbot Designed for Disease Detection

By LabMedica International staff writers
Posted on 11 Apr 2012
A “living” prototype microbot is under development that could someday identify diseases in humans.

Called Cyberplasm, it will combine advanced microelectronics with latest developments in biomimicry (technology inspired by nature). More...
The goal is for Cyberplasm to have an electronic nervous system, “eye” and “nose” sensors derived from mammalian cells, as well as artificial muscles that utilize glucose as an energy source to propel it. The key purpose is to engineer and incorporate robot components that respond to light and chemicals in the same way as biologic systems. This is a totally new way of utilizing robotics technology.

Cyberplasm is being developed over the next few years as part of an international collaboration funded by the UK Engineering and Physical Sciences Research Council (EPSRC) and the US National Science Foundation (NSF; Arlington, VA, USA). The UK-based work is taking place at Newcastle University (UK). The project originated from a sandbox session on synthetic biology jointly funded by the two organizations.

Cyberplasm will be devised to mimic key functions of the sea lamprey, a creature found mostly in the Atlantic Ocean. It is believed this application will enable the microbot to be very sensitive and responsive to any environment into which it is placed. Future uses could include the ability to swim inconspicuously through the human body to detect a wide host of diseases.

The sea lamprey [Petromyzon marinus] has a very primitive nervous system, which is easier to mimic than more complicated nervous systems. This, combined with the fact that it swims, made the sea lamprey the best candidate for the scientists on which to base Cyberplasm.

Once it is developed, the Cyberplasm prototype will be less than 1-cm long. Future versions could possibly be less than 1-mm long or even constructed on a nanoscale. “Nothing matches a living creature’s natural ability to see and smell its environment and therefore to collect data on what's going on around it,” said bioengineer Dr. Daniel Frankel of Newcastle University, who is leading the UK-based work.

Cyberplasm’s sensors are being developed to respond to external stimuli by transforming them into electronic impulses that are sent to an electronic “brain” equipped with sophisticated microchips. This brain will then send electronic messages to artificial muscles instructing them how to contract and relax, enabling the robot to navigate its way safely using an undulating motion. Similarly, data on the chemical composition of the robot’s surroundings can be collected and stored via these systems for later recovery by the robot’s operators.

Cyberplasm could also represent the beginning of important advances in, for example, sophisticated prosthetics where living muscle tissue might be engineered to contract and relax in response to stimulation from light waves or electronic signals. “We’re currently developing and testing Cyberplasm’s individual components,” stated Daniel Frankel. “We hope to get to the assembly stage within a couple of years. We believe Cyberplasm could start being used in real-world situations within five years.”

The UK component of the Cyberplasm project is a three-year initiative that is receiving EPSRC funding of just over GBP 298,000. EPSRC is the main UK government agency for funding research and training in engineering and the physical sciences, investing more than GBP 800 million a year in a wide range of topics--from mathematics to materials science, and from information technology (IT) to structural engineering.

NSF is an independent US agency created by the US Congress in 1950. With an annual budget of approximately USD 6.9 billion (FY 2010), it is the funding source for about 20% of all federally-supported basic research conducted by US colleges and universities. In many fields, such as mathematics, computer science and the social sciences, NSF is the major source of federal backing.

Related Links:

UK Engineering and Physical Sciences Research Council
US National Science Foundation
Newcastle University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.